S100A2, an EF hand calcium-binding protein, is a potential biomarker in several cancers and is also a TGF-β (transforming growth factor-β)-regulated gene in melanoma and lung cancer cells. However, the mechanism of S100A2 regulation by TGF-β and its significance in cancer progression remains largely unknown. In the present study we report the mechanism of S100A2 regulation by TGF-β and its possible role in TGF-β-mediated tumour promotion. Characterization of the S100A2 promoter revealed an AP-1 (activator protein-1) element at positions − 1161 to − 1151 as being the most critical factor for the TGF-β1 response. Chromatin immunoprecipitation and electrophoretic mobility-shift assays confirmed the functional binding of the AP-1 complex, predominantly JunB, to the S100A2 promoter in response to TGF-β1 in HaCaT keratinocytes. JunB overexpression markedly stimulated the S100A2 promoter which was blocked by the dominant-negative JunB and MEK1 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signalregulated kinase) kinase 1] inhibitor, PD98059. Intriguingly, despite the presence of a putative SMAD-binding element, S100A2 regulation by TGF-β1 was found to be SMAD3 independent. Interestingly, p53 protein and TGF-β1 show synergistic regulation of the S100A2 promoter. Finally, knockdown of S100A2 expression compromised TGF-β1-induced cell migration and invasion of Hep3B cells. Together our findings highlight an important link between the TGF-β1-induced MAPK and p53 signalling pathways in the regulation of S100A2 expression and pro-tumorigenic actions.
INTRODUCTION
Members of the S100 protein family show cell-and tissuespecific expression and are involved in a plethora of cellular processes like immune response, differentiation, cytoskeleton dynamics and cell growth [1, 2] . The majority of S100 genes are clustered in a region of human chromosome 1q21 and are frequently rearranged in a variety of cancers [3] . Interestingly, several S100 proteins, such as S100A4, S100A2 and S100A6, are specifically up-regulated in aggressive advanced metastatic tumours relative to non-invasive non-metastatic tumours [4] [5] [6] . The preferential expression pattern of these proteins in more invasive and metastatic tumours has led them to be regarded as potential prognostic and diagnostic markers [1] . The S100A2 gene encodes an 11 kDa acidic protein involved in cell-cycle regulation, cellular differentiation and chemoattraction. Altered expression of S100A2 has been implicated in several disease processes including cancer [2] . Initially S100A2 was identified as a putative tumour suppressor gene in a subtractive hybridization screen in human breast cancer cell lines [7] . In contrast S100A2 overexpression was detected specifically in basal-like breast tissues and regarded as potential target for the treatment of such breast cancers [8] . Overexpression of S100A2 has also been reported in ovarian carcinomas [9] , early stage NSCLCs (nonsmall cell lung carcinomas) [10] , mixed tumours of the skin containing neoplastic myoepithelial cells [11] , well-differentiated oesophageal squamous cell carcinomas [12] and all grades of endometrioid tumours [13] . These observations suggest an important role for S100A2 in the progression of cancer. However, the mechanism(s) of S100A2 gene regulation and the functional implication of its altered expression in tumours is not clear. We and others have identified the S100A2 gene as a novel downstream target of TGF-β (transforming growth factor-β) [14, 15] .
TGF-β is a pleotropic molecule known to influence several disease processes including tumorigenesis. Canonical TGF-β signalling involves activation of serine/threonine kinase receptors which leads to phosphorylation of SMAD2 and SMAD3 proteins. Following phosphorylation, SMAD2 and SMAD3 form complexes with SMAD4, accumulate in the nucleus and, in conjunction with a myriad of cofactors and other sequence-specific transcription factors, regulate target gene expression [16] . TGF-β is also known to influence gene expression in a SMAD-independent manner involving activation of the TAK1 (TGF-β-activated kinase 1) and MAPK (mitogen-activated protein kinase) pathways [17] . In contrast to its growth-inhibitory actions, TGF-β promotes tumour cell invasion and metastasis [16, 18] . S100A2 regulation by TGF-β1 and their association in the progression of several cancers justified the delineation of its mechanism of regulation by TGF-β and the role of S100A2 in TGF-β-mediated tumour promotion. In the present study we show that the S100A2 gene is a direct transcriptional target of TGF-β1 in epithelial cell lines through the integration of MAPK and p53 signalling pathways. Most
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importantly, the present study highlights the role of S100A2 in mediating TGF-β-induced migration/invasion of tumour cells.
MATERIALS AND METHODS

Cell culture
A549 (lung adenocarcinoma), MDA-MB231 (breast carcinoma), HBL-100 (immortalized breast epithelial) and Hep3B (hepatocellular carcinoma) cells were obtained from National Centre for Cell Sciences (Pune, India). The H1299 (p53 − / − lung adenocarcinoma) cell line was kindly provided by Dr Kumaravel Somasundaram, IISc (Indian Institute of Science; Bangalore, India) and HaCaT cells (immortalized skin keratinocyte) was obtained from Dr Sudhir Krishna (National Centre for Biological Sciences, Bangalore, India). All of the cell lines were cultured in DMEM (Dulbecco's modified Eagle's medium; SigmaAldrich) supplemented with 10 % (v/v) FBS (fetal bovine serum; Invitrogen), 100 units/ml penicillin and 100 μg/ml streptomycin (Gibco) at 37
• C in a 5% CO 2 atmosphere.
Transient transfection and reporter assays
All transfections were performed using Lipofectamine TM 2000 (Invitrogen) reagent as per the manufacturer's instructions and the reporter assays were carried out using a dual luciferase assay kit (Promega) as described previously [19] .
RNA preparation and RT (reverse transcription)-PCR
Total RNA isolation, cDNA synthesis and RT-PCR were performed as described in [14] . The expression levels were normalized to the level of RPL-35a (ribosomal protein L-35a) [20] . The quantification of the intensity of ethidium-bromidestained nucleic acids was done using Alpha digidoc 2 software (Raytest). The primer sequences used for RT-PCR are listed in Supplementary Table S1 (at http://www.BiochemJ.org/bj/447/ bj4470081add.htm).
Treatment of cells with TGF-β1 and inhibitors
Cells were cultured and serum starved for 24 h before treatment with TGF-β1 (R&D Systems) at a concentration of 5 ng/ml or 100 nM PMA (Sigma) for the various assays described below. Inhibitor treatments were done for 2-3 h prior to treatment with TGF-β1. Inhibitors for ALK-5 (SB431542), SMAD3 (SIS3), JNK-1 (c-Jun N-terminal kinase; L-form) and p38 (SB203580) were purchased from Calbiochem and used at a final concentration of 10 μM. MEK1 [MAPK/ERK (extracellular-signal-regulated kinase) kinase 1] inhibitor (PD98059, Calbiochem) was used at a concentration of 30 μM.
Cloning of the 5 flanking region of the S100A2 gene and expression constructs Approximately 2.1 kb (− 1999/ + 104) human S100A2 5 flanking sequence (sequence derived from eukaryotic promoter database, http://epd.isb-sib.ch) was PCR-amplified from human genomic DNA. Briefly, the (− 1999/ + 104) fragment was PCR-amplified using the primer set P-1999F/P + 104R. The resultant 2.1 kb fragment was inserted into the pGEM-T Easy vector (Promega) and sequenced. This fragment was further sub-cloned into the KpnI/XhoI sites of the pGL3-luciferase vector (Promega) and designated as pGL3 -1999/ + 104. Using pGL3 -1999/ + 104 as a template, two truncated S100A2 promoter reporter constructs were generated using the primer set P-1083F/P + 104R, P-968F/P + 104R, similar to the generation of pGL3-1999/ + 104. The primer sequences used for PCR amplifications are provided in Supplementary Table S1 . Transfection efficiency was normalized using pRL-TK Renilla luciferase in the various reporter assays. The p53 expression plasmid (pCep4/p53) was provided by Dr Kumaravel Somasundaram [21] . Control shRNA (short hairpin RNA) and S100A2 shRNA plasmids were obtained from Dr Etmar Bulk (University of Münster, Münster, Germany) [22] .The pcDNA3-JunB plasmid was provided by Dr Marc Piechaczyk (Institut de Génétique Moléculaire de Montpellier, Montpellier, France) and the pcDNA-JunB N construct was from Dr Mitsuyasu Kato (University of Tsukuba, Tsukuba, Japan) [23] .
Site-directed mutagenesis
Mutagenesis of potential transcription-factor-binding elements in the pGL3-1999/ + 104 promoter reporter plasmid was performed using the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. The mutants were confirmed by restriction digestion using restriction endonuclease (introduced into the mutant primers, see Supplementary Table S1 ) and DNA sequencing.
EMSAs (electrophoretic mobility-shift assays)
Nuclear extracts were prepared and the protein was quantitated by the Bradford assay as described previously [24] . EMSA probes were generated by end filling of annealed duplex oligonucleotides (that contained 5 overhangs) using Klenow polymerase and [α-
32 P]dCTP. The sequences of the probes are shown in Supplementary Table S2 (at http://www.BiochemJ.org/ bj/447/bj4470081add.htm). The sequence for the consensus SBE (SMAD-binding element) used as positive control was as described previously [25] . The labelled probes were purified on Sephadex G25 columns (Sigma-Aldrich) and 10 000 c.p.m. was used in each reaction. DNA-protein binding reactions were carried out in a 25 μl volume using 2-5 μg of nuclear extract and 1 μg of poly(dI/dC) (Sigma-Aldrich) in a binding buffer containing 10 mM Tris/HCl (pH 7.5), 0.1 mM DTT (dithiothreitol), 10 % glycerol, 5 μg BSA, 1 mM MgCl 2 and 90 mM NaCl. Competition experiments were carried out using a 40-50-fold excess of unlabelled oligonucleotides. JunB (Santa Cruz Biotechnology, sc8051x) and anti-c-Jun antibody (sc-44x) (2 μg each) were used for the supershift experiments. Nuclear extract was mixed with all components except radiolabelled probes and incubated for 10 min on ice. Subsequently, radiolabelled probes were added and incubation was carried out for 20 min. Following the incubation, the DNA-protein complexes were allowed to cross-link in a UV cross-linker (UV stratalinker, Stratagene) and electrophoresed on a 5 % non-denaturing acrylamide gel in 0.5× TBE (44.5 mM Tris, 44.5 mM boric acid and 1 mM EDTA). Gels were vacuum dried and subjected to autoradiography or phosphor imager analysis (Typhoon, GE technologies).
Western blotting
Cell extracts were prepared by scraping keratinocytes into ice cold lysis buffer [20 mM Tris/HCl (pH 7.5), 150 mM NaCl, 10 % glycerol, 1 % Triton X-100 and complete protease inhibitor cocktail (Calbiochem)] and spun in a microfuge for 10 min at 10 000 g at 4
• C. Equal amounts of protein, as determined by the Bio-Rad DC TM protein assay, were separated by 12.5-15 % polyacrylamide gel and electrophoretically transferred on to PVDF membranes (Immobilin P, Millipore). Membranes were pre-incubated for 1 h with 5 % non-fat dry milk (Fluka, Sigma-Aldrich) in TBST (Tris-buffered saline containing 0.1 % Tween 20) and then incubated with polyclonal anti-S100A2 antibody (described in Supplementary Figure  S1 at http://www.BiochemJ.org/bj/447/bj4470081add.htm). Antiphospho-ERK, anti-(total ERK), anti-phospho-SMAD2, antiphospho-SMAD3, anti-(total SMAD2/3) and anti-laminB antibodies (Cell Signaling Technology) were used at a dilution of 1:1000. Monoclonal anti-JunB and anti-β-actin (SigmaAldrich) antibodies were used at a dilution of 1:1000 and 1:3000 respectively. Washes were performed three times for 15 min in TBST at room temperature (25 • C). Membranes were incubated with appropriate horseradish-peroxidase-conjugated IgG (SigmaAldrich) at a dilution of 1:3000 for 1 h at room temperature. Detection was performed using Super Signal West Femto chemiluminescence (Pierce) as per the manufacturer's instructions.
ChIP (chromatin immunoprecipitation) assay
ChIP assays were conducted with chromatin isolated from HaCaT cells treated with 5 ng/ml of TGF-β1 for 6 h. Briefly, after crosslinking, the nuclei were prepared and sonicated to generate chromatin fragments between 100 and 1000 bp. The sheared chromatin was collected by centrifugation (12000 g for 10 min at 4
• C) and a 10 μl aliquot was removed to serve as a positive input sample. Aliquots of 100 μl sheared chromatin were incubated with 2 μg of anti-JunB antibody and Protein A/G beads (Santa Cruz Biotechnology). An equal amount of normal mouse IgG (Sigma-Aldrich) was used as a control. The immunoprecipitated DNA was analysed by PCR using the S100A2-specific primer set ChIP-F/ChIP-R (Supplementary Table S1 ) to amplify a region (− 1279/ − 924) within the S100A2 promoter. Conditions of linear amplification were determined empirically for this primer. The PCR conditions were as follows: 95
• C for 5 min; 95
• C for 30 s, 60
• C for 30 s and 72
• C for 30 s for 35 cycles. PCR products were resolved by electrophoresis on a 2 % agarose gel and visualized after ethidium bromide staining.
shRNA and siRNA (small interfering RNA) transfection
The human S100A2 siGENOME SMARTpool siRNA (catalogue number M-012191-00-0010) were obtained from Dharmacon Research. The SMARTpool siRNA is a mixture of four different siRNA duplexes targeting distinct coding region sequences of S100A2 (GenBank ® accession number NM_005978.3). The siRNA duplexes were dissolved in the 1× universal RNA oligonucleotide buffer (20 mM KCl, 6 mM Hepes/KOH (pH 7.5) and 0.2 mM MgCl 2 ). siRNA transfections (200 nM) were carried out using Oligofectamine reagent (Invitrogen) as per the manufacturer's instructions. The cells were plated for various experiments 72 h after siRNA transfection to ensure efficient knockdown. Silencing of S100A2 expression was also achieved using shRNA technology. The oligonucleotides targeting S100A2 (sense, 5 -GATGAGAACAGTGACCAGCAG-3 ; antisense, 5 -CTGCTGGTCACTGTTCTCATC-3 ; and loop, 5 -TTGATATCCG-3 ) and the scrambled control (sense, 5 -AGATCCGTATAGTGTACCTTA-3 ; antisense, 5 -TAAGGTAC-ACTATACGGATCT-3 ; and loop, 5 -TTGATATCCG-3 ) were synthesized, annealed and cloned into the shRNA expression vector pRNAT-H1.1/Neo (GenScript) [22] . shRNA-transfected Hep3B cells were used 58 h post-transfection for the in vitro assays.
Matrigel invasion and migration assays
In vitro invasion and migration assays were performed using Boyden chambers (pore size = 8 μm) coated with or without matrigel (BD Biosciences). Hep3B cells were transfected with control S100A2 shRNA or siRNA. Briefly, the control inserts or matrigel-coated inserts were rehydrated with plain DMEM for 2 h before use. These were then filled with cells after transfection and recovery (5×10 4 cells in 0.5 ml of DMEM with or without 5 ng/ml of TGF-β1), and placed in a well of a 24-well plate. At 22 h after incubation the cells on the upper side of the filters were removed with cotton-tipped swabs. Migrated and/or invaded cells on the lower side of the filters were fixed and stained with 0.05 % Crystal Violet. The cells on the underside of the filters were viewed under a microscope and counted.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 5.0 Software. Statistical significance was evaluated using either an unpaired Student's t test or one-way ANOVA using Bonferroni's post-hoc comparisons. The results are expressed as means + − S.E.M. and differences are considered significant for P<0.05.
RESULTS
TGF-β1 stimulates S100A2 expression in human epithelial cells.
In a previous microarray study, we identified S100A2 as a novel downstream target of TGF-β1 in lung epithelial cells [14] and the HaCaT cell line (P. Ranganathan and P. Kondaiah, unpublished work). TGF-β1 has been implicated in protumorigenic actions such as tumour invasion and metastasis [16, 18] . The involvement of S100A2 in several cancers and its induction by TGF-β1 prompted us to investigate the regulation of S100A2 by TGF-β1 in both normal and tumour cells. Kinetic studies in serum-starved HaCaT cells treated with TGF-β1 for various time periods (1-24 h) resulted in the increase of S100A2 mRNA expression as early as 4 h (3.24-fold) and maximal stimulation (3.93-fold) was observed at 6 h posttreatment ( Figure 1A ). Immunoblot analysis using a polyclonal antibody raised against recombinant human S100A2 showed basal expression in untreated HaCaT cells, whereas treatment with TGF-β1 caused accumulation of the S100A2 protein at 6 and 24 h ( Figure 1B ). Induction of S100A2 mRNA expression by TGF-β1 was also observed in other cell lines, such as MDA-MB231, Hep3B and HBL-100 (Supplementary Figure S2 at http://www.BiochemJ.org/bj/447/bj4470081add.htm). These findings indicated that TGF-β caused a potent and sustained increase in the S100A2 expression in both immortalized epithelial and tumour cell lines of different origins. To verify that stimulation of S100A2 expression by TGF-β1 requires active transcription and is not an effect on the stability of pre-existing S100A2 mRNA molecules, we treated HaCaT cells with TGF-β1 (5 ng/ml) for 6 h in the presence or absence of actinomycin D (5 μg/ml). Actinomycin D treatment blocked TGF-β1-induced S100A2 mRNA ( Figure 1C ) and protein ( Figure 1D ) expression. These results suggest transcriptional regulation of the S100A2 gene by TGF-β1.
TGF-β1 regulates transcription of the S100A2 gene through an AP-1 (activator protein 1) consensus element
To substantiate the transcriptional regulation of S100A2 by TGF-β1 we performed promoter reporter assays. For this, we cloned 2.1 kb of 5 flanking sequence of the S100A2 gene in a pGL3 luciferase reporter vector designated as pGL3-1999/ + 104. This construct, along with the pRL-TK vector, were co-transfected (A) A representative ethidium-bromide-stained gel showing up-regulation of S100A2 mRNA in the human HaCaT cell line. Cells were serum starved and treated ( + ) with TGF-β1 (5 ng/ml) for indicated time points or left untreated ( − ) and analysed for S100A2 expression by semi-quantitative RT-PCR. RPL-35a was used as a control. The histogram represents S100A2 abundance as fold increases (n = 3) relative to the untreated cells. Statistical significance was determined by one-way ANOVA. **P < 0.01, ***P < 0.001. ns, not significant. (B) Immunoblot analysis in HaCaT cells showing S100A2 levels upon treatment with TGF-β1 at the indicated time points. Expression of phosphorylated-SMAD2 (p-SMAD2) was used as a positive control for TGF-β1 treatment and β-actin served as the loading control. (C and D) Serum-starved HaCaT cells were exposed to 5 μg/ml of actinomycinD (ActD) for 2 h followed by stimulation with TGF-β1 (5 ng/ml) for 6 h ( + ) or left untreated ( − ). Expression of S100A2 mRNA was analysed using semi-quantitative RT-PCR and Western blotting.
in the HaCaT, HBL-100 and Hep3B cell lines followed by treatment with TGF-β1 for 24 h. TGF-β1 treatment induced S100A2 promoter activity by 3.9-, 3.2-and 2.89-fold for HaCaT, HBL-100 and Hep3B cells respectively (Figure 2A) . In order to identify the transcription factors involved in the regulation of S100A2 by TGF-β1, the − 1999 to + 104 5 flanking sequence of S100A2 was subjected to Matinspector analysis (http://www.genomatix.de). This analysis revealed the presence of consensus binding elements for several transcriptionfactor-binding sites as shown in Supplementary Figure S3 (at http://www.BiochemJ.org/bj/447/bj4470081add.htm). Notably, there are three consensus AP-1 (TGAGTCA)-binding sites (− 1191 to − 1189, − 1161 to − 1151 and − 357 to − 347, denoted as AP-1/S1, AP-1/S2 and AP-1/S3 respectively) in the S100A2 promoter ( Figure 2B ). In addition, several other transcription-factor-binding sites, such as one SBE (CAGA)-binding element (− 1055 to − 1047) and three p53-binding sites (− 1791 to − 1771, − 946 to − 926 and − 357 to − 337, denoted as p53/S1, p53/S2 and p53/S3 respectively). Two NF1 (nuclear factor 1; − 1039 to − 1021 and − 123 to − 105) sites were also identified. The region containing two of these AP-1-binding sites (− 1204 and − 1162) was earlier reported as an enhancer for S100A2 transcription [26] . The third putative AP-1 site was found to be within a p53 consensus-binding sequence at − 357 to − 337 from the transcription start site.
TGF-β is known to activate several genes, such as Timp-1 (tissue inhibitor of metalloproteinase 1), MMP-1 (matrix metalloproteinase 1) and PAI-1 (plasminogen activator inhibitor-1) via AP-1 homo-/hetero-dimeric complexes [27, 28] . To evaluate the role of AP-1 transcription factors in the regulation of S100A2 by TGF-β1, we generated two promoter deletion constructs ( Figure 2B ). Transient transfection of pGL3-1999/ + 104 in HaCaT cells increased S100A2 promoter activity 4-fold upon stimulation with TGF-β1. Also, treatment with PMA increased promoter activity 6-fold. Deletion of distal AP-1 elements (− 1191 to − 1189 and − 1161 to − 1151) lowered the basal promoter activity by approximately 9.5-fold, suggesting its major contribution in the basal expression of S100A2. Interestingly, despite the presence of SBE element in the pGL3-1083/ + 104 deletion mutant, induction of the promoter activity by TGF-β1 was not observed (Figure 2B ), indicative of SBEindependent regulation of this gene. This was further confirmed by EMSA analysis, which showed no detectable binding of any protein complex to the putative SBE consensus element in the S100A2 promoter either in the presence or absence of TGF-β1 (Supplementary Figure S4 at http://www.BiochemJ. org/bj/447/bj4470081add.htm). In good agreement, blocking SMAD3 signalling using a SMAD-specific inhibitor (SIS3) had no effect on the stimulation of S100A2 mRNA by TGF-β1 ( Figure 2C ). Interestingly, a further deletion of 30 bp ( Figure 2B ) reduced the promoter activity to about 2 % of the full-length promoter activity, indicating the presence of an essential element required for basal transcription in this region. This region has a NF1 transcription-factor-binding site which is known to regulate basal transcription of several genes [29] . These data suggest an important role for the distal AP-1 enhancer and NF1 element in the expression of S100A2. Furthermore, the induction of S100A2 by TGF-β1 involves the distal AP-1 element without direct involvement of SMAD3.
In order to ascertain the role of each AP-1-binding site in the basal transcription and regulation of S100A2 by TGF-β1, sitedirected mutants of individual AP-1 elements were generated and luciferase assays were performed in HaCaT cells. Transfection of individual AP-1 mutant constructs indicated a significant contribution of all AP-1 elements to the basal promoter activity of S100A2. Mutation of the distal most AP-1 element (AP-1/S1) led to approximately 5-fold reduction in the basal promoter activity, but TGF-β1 inducibility of the promoter was not compromised. Intriguingly, mutation of the second AP-1 element (AP-1/S2) drastically brought down the basal expression of this promoter and there was complete loss of induction by TGF-β1. Mutation in the third AP-1 element (AP-1/S3) resulted in a marginal decrease in the basal promoter activity (∼ 1.7-fold), but there was no compromise on the TGF-β1 induction as the fold induction was comparable with the full-length promoter ( Figure 2D ). Taken together, these results suggests that the AP-1 element at position − 1161 (AP-1/S2) appears to be the most critical enhancer for basal expression of S100A2 as well as for TGF-β-mediated stimulation of S100A2 expression.
Regulation of S100A2 by TGF-β is JunB dependent
In order to demonstrate the functional binding of AP-1 transcription factors to the identified elements in the 2.1 kb S100A2 promoter, we performed EMSA experiment with all three α-32 P-labelled AP-1 oligoduplexes. All three of the labelled AP-1 oligoduplexes showed retardation in electrophoretic mobility upon incubation with TGF-β1-treated HaCaT nuclear extract and were efficiently outcompeted with excess of unlabelled oligoduplexes ( Figure 3A and Supplementary Figure  S5 at http://www.BiochemJ.org/bj/447/bj4470081add.htm). To confirm AP-1 complex binding to these oligoduplexes, supershift with anti-JunB and anti-c-Jun antibody was performed. As shown in Figure 3 (A) and Supplementary Figure S5(A) , supershift was seen with the anti-JunB antibody and there was no reactivity seen with the anti-c-Jun antibody (results not shown). To study the functional relevance of JunB binding to the S100A2 promoter elements, the S100A2 promoter was co-transfected with a JunB expression construct in HaCaT cells and luciferase activity was measured. As shown in Figure 3(B) , S100A2 promoter activity increased by 4.36-fold in the presence of JunB with or without TGF-β addition. However, the basal activity of the S100A2 promoter increased by ∼ 3-fold upon JunB overexpression. Expression of dominant-negative JunB completely abolished TGF-β-mediated induction of the S100A2 promoter ( Figure 3B ). Finally, in vivo ChIP with an anti-JunB antibody established increased JunB occupancy to distal AP-1 enhancer in the S100A2 promoter in the presence of TGF-β1 ( Figure 3C ). These data complex on the S100A2 promoter. Cells were treated with TGF-β1 (5 ng/ml) for 6 h ( + ) or left untreated ( − ) and processed for the assay with the indicated antibodies as described in Materials and methods section. Normal mouse IgG was used as a negative control. Immunoprecipitated DNA was amplified with primers (see Supplementary Table S1 at http://www.BiochemJ.org/bj/447/bj4470081add.htm) spanning the region (− 1279/ − 924) of the S100A2 promoter.
indicate an essential role for JunB in the regulation of S100A2 by TGF-β.
TGF-β1 mediates S100A2 induction through activation of MEK/ERK signalling
To elucidate the signalling pathways involved in the transcriptional activation of S100A2 by TGF-β through AP-1 factors, we treated HaCaT cells using pathway-specific smallmolecule inhibitors in the presence or absence of TGF-β1. AP-1-mediated transcription can be activated by the action of MAPK signalling, involving either the MEK/ERK/p38 or JNK pathways [30, 31] . Blocking MEK/ERK signalling with the MEK1 inhibitor PD98059 completely abolished TGF-β1-dependent upregulation of S100A2 mRNA expression ( Figure 4A ). However, inhibition of either the JNK or p38 pathway had no effect on S100A2 mRNA induction by TGF-β1 (Supplementary Figure  S6 at http://www.BiochemJ.org/bj/447/bj4470081add.htm). This indicated that activation of S100A2 by TGF-β1 is MEK/ERK dependent. In good agreement, PD98059 completely blocked ERK activation by TGF-β1 as seen by the loss of ERK1/2 phosphorylation, induction of S100A2 protein expression ( Figure 4B ) and binding of the AP-1-JunB complex to the S100A2 promoter element ( Figure 4C ). This establishes that regulation of S100A2 transcription by TGF-β1 is mediated by MEK/ERK activation of AP-1 protein.
Synergistic regulation of S100A2 by p53 and TGF-β1 signalling
Wild-type p53 and its family members are known to stimulate S100A2 transcription [2] . Several recent observations have linked AP-1 to the modulation of the p53 pathway to explain the role of AP-1 in cell survival [32] . Under some circumstances p53 can even induce expression of the genes encoding different AP-1 components [33] . Since both TGF-β and p53 regulate S100A2 expression, we speculated a co-regulation of S100A2 by both these factors. To address this, we performed promoter reporter assays in the p53 mutant HaCaT cell line and the p53-null H1299 cells by ectopic expression of wild-type p53, followed by TGF-β1 treatment. In the HaCaT cells, wild-type p53 and TGF-β1 were able to stimulate S100A2 promoter activity by 7.8-and 4.2-fold respectively. Significantly, p53, in the presence of TGF-β1, induced S100A2 transcription 57.3-fold ( Figure 5A ). Furthermore, in p53-null H1299 cells, TGF-β1 and p53 induced S100A2 promoter activity by 2-and 3-fold respectively. Similar to the regulation in HaCaT cells, TGF-β1 and p53 together induced S100A2 promoter by 11.3-fold in the H1299 cell line ( Figure 5B ). We further evaluated the role of p53-binding elements in the p53/TGF-β synergistic regulation of the S100A2 promoter. As shown in Figure 2(B) , there is a possible involvement of a distal p53 element (p53/S1, at − 1791) in the regulation of S100A2 by TGF-β. In order to understand the role of distal and proximal putative p53 elements, we generated site-directed mutants of p53-binding sites (p53/S1) and (p53/S2). These promoter constructs (A-C) HaCaT cells were serum starved for 24 h and then incubated with TGF-β1 (5 ng/ml) for 24 h before ( − ) or after ( + ) pre-treatment with 30 μM PD98059 for 2 h. (A) RNA was extracted and processed for RT-PCR analysis with primers specific against the S100A2, PAI-1 and p21 genes. RPL-35a was used for normalization. Histogram shows the fold increase compared with the untreated cells for same period of time, the value of which was considered as 1. (B) Immunoblot with antibodies against S100A2, phosphorylated ERK1/2 (p ERK1/2), total ERK1/2 and β-actin. (C) EMSA using HaCaT nuclear extract (Nuc Ext) treated with MEK inhibitor was performed as described above. The extracts were incubated with AP-1/S2 wild-type (WT) probe from the human S100A2 promoter. The arrow indicates the specific DNA-protein complex. The complex was competed by a molar excess of unlabelled (cold) AP-1/S2. *, anti-JunB antibody used for supershift.
were tested for inducibility by TGF-β and their role in p53/TGF-β synergism. Mutation of either of the p53-binding elements did not affect induction of the S100A2 promoter by TGF-β ( Figure 5C ), suggesting that inducibility of S100A2 by TGF-β is independent of p53-binding elements. Interestingly, mutation of a proximal p53 element (p53/S1) abolished the synergism that was observed with p53 expression and treatment with TGF-β. However, there was no loss of synergism observed when the p53/S2 element was mutated. This suggests that the distal p53 element (p53/S1) is important for p53 regulation as well as p53-and TGF-β-mediated synergism of S100A2 promoter. Taken together, these results demonstrate a synergistic regulation of S100A2 by the TGF-β1 and p53 signalling pathways.
Knockdown of S100A2 compromises TGF-β-induced tumour cell migration and invasion S100A2 overexpression has been correlated with increased cell migration and metastasis [10, 22] . Also, the MAPK pathway has been implicated in TGF-β1-induced pro-tumorigenic actions [16] [17] [18] . Since regulation of S100A2 by TGF-β1 requires activation of MAPK signalling, we investigated the role of S100A2 in mediating TGF-β1-induced migration and invasion using Hep3B cells. We used Hep3B cells for TGF-β-mediated migration/invasion studies due to following reasons: Hep3B cells express higher levels of S100A2 mRNA which is efficiently induced by TGF-β1 (Supplementary Figure S2) and TGF-β1 treatment stimulates S100A2 promoter activity (Figure 2A ) in these cells which are known to undergo EMT (epithelialmesenchymal transition) in response to TGF-β [34] . In order to understand the functional significance of S100A2 regulation by TGF-β in Hep3B cells, knockdown of S100A2 expression was performed using shRNA and siRNA. Efficient knockdown of S100A2 mRNA and protein expression was confirmed by RT-PCR and immunoblot analysis compared with the cells transfected with control ( Figures 6A and 6B) . The effect of S100A2 knockdown on the migratory ability of cells was assessed in vitro, using transwell migration chambers. Hep3B cells transfected with control shRNA or siRNA showed a significant increase in the migration upon stimulation with TGF-β1. However, knockdown of S100A2 significantly decreased (P < 0.001) TGF-β1-induced cell migration ( Figure 6C ). In addition, S100A2 knockdown compromised TGF-β-mediated invasion of Hep3B cells (P < 0.01) in the matrigel invasion assay ( Figure 6D ). Collectively these results highlight an important function of S100A2 in mediating TGF-β1-induced cell migration and invasion. HaCaT (mutant p53) and H1299 (p53-null) cells were co-transfected with the pGL3-1999/ + 104 reporter along with empty vector or plasmid encoding a human p53 expression plasmid and pRL-TK. At 24 h post-transfection cells were treated with TGF-β1 (5 ng/ml) for another 24 h and luciferase activity was measured as described above. (C) HaCaT cells were co-transfected with site-specific p53 mutant constructs (as shown on the left-hand side) and pRL-TK. At 24 h post-transfection the cells were treated with TGF-β1 (5 ng/ml) and luciferase (LUC) activity was measured 24 h post-treatment. (D) HaCaT cells were co-transfected with pGL3-1999/ + 104 reporter or p53/S1 and p53/S2 mutant (mut) reporter plasmids along with empty vector or plasmid encoding a human p53 expression plasmid and pRL-TK. Cells were treated with TGF-β1 (5 ng/ml) as described above and luciferase activity was measured. The values on top of the columns indicate the fold change in luciferase activity compared with the respective untreated bars. The results are means + − S.E.M. derived from three independent experiments performed in triplicates per group and analysed by one-way ANOVA. ***P < 0.001.
Figure 6 S100A2 is required for TGF-β-induced cell migration and invasion
Hep3B cells were transfected with the indicated shRNA plasmids or SMART pool siRNA. (A) Ethidium bromide gel showing expression of S100A2 and RPL-35a. RNA was isolated post-transfection and subjected to semi-quantitative RT-PCR analysis. Specific primers for the detection of S100A2 and RPL-35a transcripts were used. (B) Equal amounts of lysates from control and knockdown Hep3B cells was subjected to Western blotting to detect the levels of S100A2 and β-actin proteins. The percentage migration (C) and invasion (D) of either control or S100A2-knockdown Hep3B cells was determined based on the BD TM Matrigel assay as per the manufacturer's instructions. Results are means + − S.E.M., representative of two independent experiments performed in duplicate for shRNA and triplicate for siRNA in each group. Two-way ANOVA was used to determine if the differences in their percentage migration and invasion were significant (***P < 0.001, **P < 0.01).
DISCUSSION
The TGF-β signalling pathway plays a pivotal role in diverse cellular processes ranging from development to carcinogenesis. However, its role in cancer progression is highly complex. TGF-β functions as a tumour suppressor in normal or dysplastic cells and as a tumour promoter in advanced cancers ( [16] and references within). TGF-β mediates its growth inhibitory or tumour-promoting actions by regulating the expression of its target genes in a cellular context-dependent manner. This has led to the identification and characterization of several novel TGF-β effectors, such as c-Myb [35] and Pin1 (peptidylprolyl cis/trans isomerase, NIMA-interacting 1) [36] which are shown to mediate pro-tumorigenic actions of TGF-β. Members of the S100 family of proteins, including S100A2, show altered expression in several cancers. Wang et al. [37] and Diederichs et al. [10] reported S100A2 as a prognostic marker or a predictor of distant metastasis in patients with early-stage NSCLC. In a previous report, we identified S100A2 as a downstream target of TGF-β signalling [14] . Other S100 members like S100A4 and S100A11 are reported to be regulated by TGF-β [13, 38] . However, the mechanism of regulation for any S100 family proteins by TGF-β has not been studied so far. S100A2 transcriptional regulation has been extensively studied with regard to p53 and its family members [2] . Also EGF (epidermal growth factor) was shown to regulate S100A2 transcription [39] . However, the functional significance of S100A2 regulation by these molecules has not been elucidated. In view of TGF-β's role in tumour promotion and regulation of S100A2, we investigated its mechanism of regulation by TGF-β and its functional significance which might provide vital clues for the role of S100A2 in tumour promotion. In the present study we demonstrate the transcriptional regulation of S100A2 by TGF-β in epithelial cells. Further, our data highlights an important role for AP-1 transcription factors in the regulation of S100A2 by TGF-β. By promoter deletion, site-directed mutagenesis, EMSA and ChIP studies, we were able to establish a crucial role for AP-1/JunB protein binding to the enhancer of S100A2 promoter in response to TGF-β1. Interestingly, this enhancer was shown to be critical for its basal transcription in both normal and tumour cell lines [7] . Our findings are in agreement with this previous study and identify the mechanism by which this enhancer brings about S100A2 expression in response to TGF-β1. We also show that JunB binding to the S100A2 promoter is due to activation of TGF-β1 induced MEK/ERK signalling. Interestingly, wild-type p53 and TGF-β synergizes induction of S100A2 promoter activity. The convergence of p53 and TGF-β signalling has been shown in the regulation of a few genes, like maspin and PAI-1. However, this regulation involves cooperation with SMADs bound to its consensus sequence ( [40, 41] and references within). An earlier report suggests interaction of SMADs with all members of AP-1 proteins [42] and also with p53 upon activation of Ras/MAPK by TGF-β [43] . However, blocking SMAD3 signalling with a SMAD3-specific inhibitor did not show any significant effect on S100A2 induction by TGF-β. This suggests SMAD3-independent regulation of S100A2 by TGF-β, although we do not rule out indirect involvement of other SMADs in this regulation. The synergism of p53 and TGF-β/MAPK signalling in the regulation of S100A2 represents a unique pattern of co-operation between a tumoursuppressor pathway and a tumour-promoting MAPK pathway without direct involvement of SMADs. Finally, the present study also highlights a novel function of S100A2 in mediating TGF-β-induced cell migration and invasion. This suggests an important role for S100A2 in tumour promotion. The expression of S100A2 is a poor prognostic indicator in NSCLC and pancreatic cancer [37, 44] . In a previous study, attempts to evaluate prognosis of NSCLC using expression of S100A2 and p53 status did not provide a significant correlation [45] . In this regard the findings of the present study warrants clinical evaluation of human tumours with respect to S100A2 expression coupled with TGF-β signalling and/or p53 status.
In conclusion, we demonstrate a novel synergistic regulation of S100A2 by p53-protein-and TGF-β-induced MAPK signalling, and involvement of S100A2 in TGF-β-mediated pro-tumorigenic actions.
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SUPPLEMENTARY ONLINE
METHODS
Generation of polyclonal antibody against recombinant human S100A2
Full-length cDNA of S100A2 was PCR-amplified from total RNA obtained from human HaCaT cell line. The fragment was cloned into the XhoI/EcoRI site of the pGEX-4T1 expression vector (GE Healthcare), and verified by sequencing. This plasmid was used to transform Escherichia coli strain BL21(DE3)-pLysS cells. For protein expression, cells harbouring the S100A2 plasmid were grown to a D 600 of 0.5 and induced by adding 1 mM IPTG (isopropyl thio-β-D -galactopyranoside) for 6 h. Cells were harvested by centrifugation and lysates were used for purification of S100A2 using GSH (glutathione) beads (Novagen). The purity of the protein was confirmed by SDS/PAGE and Coomassie Blue staining of the gel. Rabbits were immunized with the antigen suspension mixed with an equal volume of the Freund's complete adjuvant (Sigma-Aldrich). Booster immunizations were given by injecting antigen suspension mixed with Freund's incomplete adjuvant. The animal experiments were carried out as per the guidelines of the institutional ethical committee after obtaining their approval. The antibody titres were determined at intervals of 4 weeks using ELISA. Antibody specificity was tested by decreasing the amount of recombinant protein in Western blot analysis (results not shown). Nuclear extract (Nuc Ext) obtained from HaCaT cells treated with or without TGF-β1 were incubated with α-32 P-labelled SBE control consensus oligoduplex (lanes 1-6) and putative SBE oligoduplex from the S100A2 promoter (lanes 7-12). The DNA-protein interaction was analysed by separating the oligoduplex on a 5 % non-denaturing PAGE in TBE buffer as described in the Materials and methods section of the main text. The gel was vacuum dried and exposed to phosphor imager. Specificity of binding was achieved by performing competition experiments with 40× excess of the respective unlabelled oligoduplex probes (lanes 6 and 12). HaCaT nuclear extract (Nuc Ext; 2 μg) pre-treated with TGF-β1 (5 ng/ml) for 24 h was incubated with a wild-type α-32 P-labelled AP1/S1 or AP1/S3 probe. Competition of the complex was performed using 40-fold excess of either respective wild-type or the mutant non-radiolabelled (cold) probe. *SS, supershift with an anti-JunB antibody. Serum-starved HaCaT cells were treated for 2 h with 10 μM SB203580, JNK inhibitor and 30 μM of PD98059 prior to treatment with 5 ng/ml TGF-β for 24 h. cDNA equivalent to 10 ng of total RNA was used for real-time RT-PCR analysis using the Dynamo SYBR Green mix (Finnzyme) in a ABI Prism 7900 HT sequence detection system (Applied Biosystem). Results are mean+ − S.E.M. fold change over control normalized to RPL-35a expression. All PCRs were done in duplicate. Sense, 5 -GGAGGAGGGTGTGCCAAGCTTTCACTGCCTGGGCATCTG-3 Antisense, 5 -CAGATGCCCAGGCAGTGAAAGCTTGGCACACCCTCCTCC-3 AP1/S2m
Sense, 5 -GGCCTGGAACCTCGGAAGCTTTCATTAGGGCTGAGG-3 Antisense, 5 -CCTCAGCCCTAATGAAAGCTTCCGAGGTTCCAGGCC-3 API/S3m
Sense, 5 -CACACAGGAGTGGGCAAGCTTTCACAGGCATGTCATGAG-3 Antisense, 5 -CTCATGACATGCCTGTGAAAGCTTGCCCACTCCTGTGTG-3 p53/S1m
Sense, 5 -GCAACTGCCCAGGCTAGCTGGTATGTGGTG-3 Antisense, 5 -CACCACATACCAGCTAGCCTGGGCAGTTGC-3 p53/S2m
Sense, 5 -GTCTGGGGAGGAGATCTGTGTGGGGGGC-3 Antisense, 5 -GCCCCCCACACAGATCTCCTCCCCAGAC-3 P-1083F/P + 104R F, 5 -ATGGTACCTGGGGCCACAGGAAGG-3 R, 5 -GACTCGAGAGCAGGACAGAGGTACTCACC-3 P-968F/P + 104R F, 5 -ATGGTACCCCACAGTGTTTGCCTTTC-3 R, 5 -GACTCGAGAGCAGGACAGAGGTACTCACC-3 P-1999F/P + 104R F, 5 -CAGGTACCCATGTGCAGAATGTGGTTTGTT-3 R, 5 -GACTCGAGAGCAGGACAGAGGTACTCACC-3 ChIP F, 5 -TTCCCTGCCAGGCTGGGCTGGGGCTT-3 R, 5 -CCCCACACACATGTCCTCCCCAGACC-3 
